5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy

Drugs

Volumn 55, Issue 2, 1998, Pages 173-189

  Gregory, R Elizabeth ^a   Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOLASETRON MESILATE; GRANISETRON; MU OPIATE RECEPTOR; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN RECEPTOR; TROPISETRON; ANTIEMETIC AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

BINDING AFFINITY; CHEMICAL STRUCTURE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; METHODOLOGY; NAUSEA; REVIEW; RISK FACTOR; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; NEOPLASM;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NAUSEA; NEOPLASMS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0031594743     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855020-00002     Document Type: Review

References (65)

1. Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987; 293: 34-44
2. Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy: predictive models for evaluation of new compounds. Drugs 1997 Feb; 53 (2): 206-34
3. Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985; 7: 191-211
4. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497-9
5. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anticancer therapy. Trends Pharmacol Sci 1988; 9: 334-41
6. Leslie RA, Shah Y, Thejomayen M, et al. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 279-88
7. Alfieri AB, Cebeddu LX. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629-32
8. 3 receptors and cytotoxic drug-induced vomiting. Trends Pharmacol Sci 1987; 8: 44-5
9. 3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol 1995; 35: 845-55
10. Blower P. A pharmacologic profile of oral granisetron. Semin Oncol 1995 Aug; 22 (4 Suppl. 10): 3-5
11. Sancillo LF, Pinkus LM, Jackson CB, et al. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents. Eur J Pharmacol 1990; 181: 303-6
12. Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301-312
13. Andrews PLR, Blower PR. The physiology of cytotoxic-induced emesis: new insights. Presented at a Satellite to the Seventh European Conference of Clinical Oncology Meeting; 1993 Nov; Jerusalem, 14-7
14. Andrews PLR, Bhandari P, Davey PT, et al. Are all 5-HT receptor antagonists the same? Eur J Cancer 1992; 28 Suppl. A: S2-6
15. Lazarus HM, Bryson JC, Lemon E, et al. Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation. J Natl Cancer Inst 1990; 82: 1776-8
16. Addelman M, Erlichman C, Fine S, et al. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990; 8: 337-41
17. Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1984; 24: 45-9
18. 3 antagonist. Br J Cancer 1988; 58: 651-3
19. de Bruijn KM. Tropisetron: a review of the clinical experience. Drugs 1992; 43 Suppl. 3: 11-22
20. Shah AK, Bhargava VO, Hahne WF, et al. Population pharmacokinetics and pharmacodynamics of metabolite after intravenous administration of dolasetron mesylate in patients receiving cisplatin chemotherapy [abstract]. Pharm Res 1995; 12 Suppl. 9: S360
21. Bonneterre J, Hecquet B, French Northern Oncology Group. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a cross-over study. Bull Cancer 1995 Dec; 82: 1038-43
22. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994; 30 (8): 1083-8
23. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995 May; 13 (5): 1242-8
24. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994; 51: 113-8
25. Stewart A, McQuade B, Cronje JDE, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double dummy, randomised, parallel-group study. Oncology 1995; 52: 202-10
26. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994 Oct; 74 (7): 1945-52
27. Martoni S, Angelelli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: an open randomized cross-over study [abstract]. Proc Am Soc Clin Oncol 1993; 13: 431
28. Leonardi V, Iannitto E, Meli M, et al. Ondansetron vs granisetron in the control of chemotherapy induced acute emesis: a multicentric randomized trial. Oncol Rep 1996; 3: 919-23
29. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995 Oct; 6: 805-10
30. Marty M, Kleisbauer J-P, Fournel P, et al. Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995; 6 Suppl. I: 15-21
31. Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol 1942; 31 (3): 573-5
32. Campora E, Simoni C, Rosso R. Tropisetron verso ondansetron nella prevenzione e controllo dell'emesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operato. Minerva Med 1994; 85: 25-31
33. 3 receptors [abstract]. Ann Oncol 1994; 5 Suppl. 8: 204
34. 3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer [abstract]. Proc Soc Am Clin Oncol 1994; 13: 428
35. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer 1993; 29A: 1669-72
36. Hesketh P, Navari R, Grote T, et al. Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996 Aug; 14 (8): 2242-9
37. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996 May; 32A (5): 807-13
38. Lofters WS, Zee B, Dolasetron (DOL) vs ondansetron (OND) with and without dexamethasone (DEX) in the prevention of nausea (N) and vomiting (V) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract]. Cancer Support Care 1995; 3: 339
39. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996 Aug; 32A (9): 1523-9
40. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9
41. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion [letter]. N Engl J Med 1983; 309: 796
42. Triozzi P, Laszlo J. Optimum management of nausea and vomiling in cancer chemotherapy. Pract Ther Drugs 1987; 24: 136-49
43. Tonato M, Roila F. Methodology of antiemetic trials. Ann Oncol 1991; 2: 107-14
44. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985 Oct; 3 (10): 1379-84
45. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-93
46. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585-8
47. Roila F, Ballatori E, De Angelis V. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995 Jan; 332: 1-5
48. Tonato M, Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. Eur J Cancer 1991; 27 Suppl. I: S12-4
49. Diehl V, Marty M. Efficacy and safety of antiemetics. Cancer Treat Rev 1994; 20: 379-92
50. Lee CR, Plosker GL, McTavish D. Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925-43
51. SmithKline Beecham Pharmaceuticals. Granisetron prescribing information. Philadelphia (PA), 1994
52. Glaxo Wellcome. Ondansetron prescribing information. Research Triangle Park (NC), 1995
53. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 208-14
54. Wilder-Smith OHG, Borgeat L, Chappuis P, et al. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993; 72: 2239-41
55. Gandara DR, Harvey WH, Monaghan GG, et al. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992 Aug; 19 (4 Suppl. 10): 67-71
56. De Mulder PHM, Seynaeve C. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40
57. Jantunen IT, Flander MK, Heikkenin MI, et al. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. Acta Oncologica 1993; 32 (4): 413-5
58. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-7
59. Navari RM, Madajewica S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995 Sep; 13 (9): 2408-16
60. Rosso R, Campora E, Cetto G, et al. Oral ondansetron (GR 38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res 1991; 11: 937-40
61. de Wit R, de Boer-Dennert M, Stoter G, et al. Sustainment of efficacy of tropisetron during 6 courses of cisplatin-containing chemotherapy [abstract]. Ann Oncol 1993; 3 Suppl. 5: 185
62. 3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail. Cancer 1994 Jan; 73: 445-54
63. Granisetron Study Group. Incidence of delayed cisplatin-induced emesis following acute antiemetic prophylaxis with granisetron. Presented at Advances in Emetic Control. 15th Union Against Cancer: 1990 Aug 17; Hamburg
64. Heron JF, Goedhals L, Jordan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1995; 5: 579-84
65. Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994; 2: 297-300